Format

Send to

Choose Destination
Int J Pharm. 2019 Feb 10;556:136-141. doi: 10.1016/j.ijpharm.2018.11.075. Epub 2018 Dec 11.

Use of a water-based probiotic to treat common gut pathogens.

Author information

1
UCL School of Pharmacy, University College London, 29-39 Brunswick Square, London WC1N 1AX, UK.
2
UCL School of Pharmacy, University College London, 29-39 Brunswick Square, London WC1N 1AX, UK. Electronic address: s.gaisford@ucl.ac.uk.

Abstract

This work reports the anti-pathogenic effect of a commercially available water-based probiotic suspension, Symprove™, against three commonly encountered infectious organisms; Escherichia coli, methicillin-resistant Staphylococcus aureus (MRSA) and Shigella sonnei. An isothermal calorimetric assay was used to the monitor growth of the species individually and in binary combinations, while colony plate counting was used to enumerate viable cell numbers. It was observed that all pathogenic species were faster growing than the probiotic bacteria in Symprove™ after inoculation into growth medium yet in all instances bacterial enumeration at the end of the experiments revealed a significant reduction in the pathogen population compared with the controls. A control population between 108 and 109 CFU/ml was obtained for E. coli and S. sonnei whilst approximately 106 CFU/ml was obtained for MRSA. Upon co-incubation for 48 h, no viable counts were obtained for E. coli; a 4-log reduction was obtained for S. sonnei whilst MRSA numbers were down to less than 10 cells/ml. The results show that Symprove™ has antipathogenic activity against E. coli, S. sonnei and MRSA.

KEYWORDS:

Infectious diseases; Lactobacilli; MRSA; Shigella sonnei, Escherichia coli

PMID:
30543889
DOI:
10.1016/j.ijpharm.2018.11.075
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center